A Bei­jing-based rare dis­ease and on­col­o­gy play­er has raised $98 mil­lion to help fund the ex­pan­sion of its pipeline as well as a com­mer­cial port­fo­lio.

CAN­bridge put out word Tues­day that the glob­al pri­vate eq­ui­ty play­er Gen­er­al At­lantic joined forces with Chi­nese CRO Wuxi AppTec to lead the Se­ries D, with both ready to chip in an ex­tra $10 mil­lion each un­der the right con­di­tions. The syn­di­cate in­cludes RA Cap­i­tal Man­age­ment, Hud­son Bay Cap­i­tal Man­age­ment, Yuan­Ming Pru­dence Fund and Tigermed.

The new in­fu­sion sets CAN­Bridge up for an IPO in a year or two, ac­cord­ing to CFO Glenn Has­san.

A spe­cial­ist in rare ge­net­ic dis­eases, CAN­bridge has been col­lab­o­rat­ing with WuXi Bi­o­log­ics, a sis­ter com­pa­ny of the CRO, on dis­cov­er­ing and de­vel­op­ing new drugs for its tar­get in­di­ca­tions.

Like a num­ber of top Chi­na drug play­ers, CAN­bridge is get­ting start­ed with some ex­ist­ing meds in-li­censed for the Asian mar­ket while fol­low­ing up with some more orig­i­nal work. Its drug Hunterase is an en­zyme re­place­ment ther­a­py un­der re­view now by Chi­nese reg­u­la­to­ry au­thor­i­ties. And the biotech has high hopes for Ner­l­ynx, the breast can­cer drug from Puma.

CAN­bridge has about 60 staffers on the ground in Chi­na, about half of whom sup­port the com­mer­cial or­ga­ni­za­tion, CEO James Xue told End­points News from their Cam­bridge, MA of­fice.

“We are def­i­nite­ly build­ing what I would say as one of the most ro­bust com­mer­cial plat­form for rare dis­ease in the Greater Chi­na re­gion that would re­al­ly en­able us to do what we call high-touch launch and op­er­a­tions of rare dis­ease prod­ucts,” he said.

Hav­ing repo­si­tioned the com­pa­ny to fo­cus on rare dis­ease rather than just on­col­o­gy, Xue — the for­mer gen­er­al man­ag­er of Gen­zyme — said the Chi­nese mar­ket is warm­ing up to rare dis­ease drugs. Take the up­take of Cerezyme, which launched in Chi­na in 2008 un­der his watch. It wasn’t un­til the end of 2012 that en­zyme re­place­ment ther­a­py re­ceived mu­nic­i­pal re­im­burse­ment from Shang­hai; but in the fol­low­ing years cov­er­age has ex­pand­ed in­to about 10 provinces and cities, with up to 100% cov­er­age.

Aware­ness is al­so clear­ly spread­ing from the pa­tient and physi­cian lev­el to the pol­i­cy­mak­ers, with rare dis­ease lan­guage and lists of­fi­cial­ly writ­ten in­to law. And the ag­gres­sive price ne­go­ti­a­tions that gov­ern­ment of­fi­cials have been do­ing for the Na­tion­al Re­im­burse­ment Drug List is a sign that they are mak­ing room for dis­eases cur­rent­ly com­plete­ly un­cov­ered, he added.

“Those are the el­e­ments or the mov­ing parts grad­u­al­ly in place that would al­low us to hope for and al­so plan for rare dis­ease mar­ket in a way that its re­im­bursed mar­ket is around the cor­ner,” he said.

So­cial im­age: James Xue, CAN­bridge CEO

Despite all the excitement over the possibility of T cell therapies to crack the code against solid tumors, early safety data have limited the burgeoning field’s promise. A clutch of players hope to solve that problem by “masking” their drugs, and now one of those outfits has snared fresh investor cash to take its shot in the clinic.

Amunix closed a $117 million Series B to guide AMX-818, a masked protease-activated T cell engager for HER2 expressing tumors, to the clinic as well as shepherding its bustling pipeline of tumor hunters through the preclinical stage, the company said Thursday.

The jury’s still out on whether the first wave of AI companies can significantly change drug development, but investors are increasingly buying into the hype.

Exscientia, the decade-old UK machine learning outfit, announced Thursday that they’ve expanded their Series C, first announced in May, from $60 million to $100 million. The expansion most notably includes BlackRock, the private equity firm that has been wading deeper and deeper into biotech. They now join Novo Holdings, Bristol Myers Squibb and others among the company’s most recent backers.

CRLs. 483s. CBER, CDER and RWE. For biopharma professionals, these acronyms command attention because of the fundamental role FDA plays in drug development. Now Endpoints is doubling down on regulatory coverage, and launching a weekly report focusing on developments out of White Oak, with analysis and insight into what it all means.

Coverage will be led by our new senior editor, Zachary Brennan. He joins Endpoints from POLITICO, where he covered pharma. Prior to that he was the managing editor for Regulatory Focus, a news publication from the Regulatory Affairs Professionals Society.